The Sire Group Ltd Says Expect To Propose To Titan Pharmaceuticals Inc A Business Combination With KE Sdn. Bhd
$TTNP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
- SEC 13D/Amended Filing
After giving effect to these changes in membership, as of April 2, 2024, four of the board's seven directors had been nominated by the reporting persons. The reporting persons expect to propose to the Issuer a business combination with KE Sdn. Bhd., a Malaysian company. Any such transaction would be subject to execution of definitive documents negotiated between the reporting persons and a committee of independent directors of the Issuer. This report does not constitute an offer of any securities for sale.